Board of Directors

Dr. Baynes has served as a member of our board of directors since July 2018. Since July 2022, Dr. Baynes has served as executive vice president and chief medical officer of Eikon Therapeutics, Inc., a privately-held biotechnology company. Previously, Dr. Baynes served as senior vice president and head of global clinical development at Merck Research Laboratories, the research division of Merck and Co., Inc., beginning in 2013, and as chief medical officer of Merck and Co, Inc., a global healthcare company, beginning in 2016. Prior to joining Merck Research Laboratories, Dr. Baynes served as senior vice president of oncology, inflammation and respiratory therapeutics at Gilead Sciences Inc., a biotechnology company, from 2012 to 2013 and the vice president global development and therapeutic area head hematology oncology at Amgen Inc., a biopharmaceutical company, from 2002 to 2012. Before joining Amgen, Dr. Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute-designated Comprehensive Cancer Center, at Wayne State University. Dr. Baynes has served as a director of Travere Therapeutics Inc. (formerly known as Retrophin, Inc.), a biopharmaceutical company, since July 2016, of Aardvark Therapeutics, Inc., a biopharmaceutical company, since December 2024, and of Nurix Therapeutics, Inc., a biopharmaceutical company, since February 2025, and previously served as a director of Atara Biotherapeutics, Inc., a biopharmaceutical company, from September 2018 until December 2022. Dr. Baynes also serves as a director of two privately held biotechnology companies. Dr. Baynes holds an M.D. and a Ph.D. from the University of the Witwatersrand, Johannesburg, South Africa. 

Monica Bertagnolli, M.D., previously served on Natera’s board of directors from November 2020 to August 2022, when she resigned due to her appointment as Director of the National Cancer Institute (NCI). Dr. Bertagnolli rejoined the Natera board in March 2025.

Most recently, Bertagnolli served as director of the National Institutes of Health from 2023 to January 2025. Earlier in her career, she held various roles at Harvard Medical School, including professor of surgery in the field of surgical oncology. During this time, Bertagnolli was also an associate surgeon in the Surgical Oncology division at Brigham and Women’s Hospital and Dana-Farber Cancer Institute; she was previously, chief of the Surgical Oncology division at Brigham and Women’s Hospital and Dana-Farber/Brigham and Women’s Cancer Center.

Bertagnolli currently serves on the board of directors of Friends of Cancer Research, and on the scientific advisory board of a private biopharmaceutical company. She previously served, among others, as chair of the board of directors of the American Society of Clinical Oncology (ASCO); as group chair and president of the Alliance for Clinical Trials in Oncology Foundation; and as chief executive officer of Alliance Foundation Trials, LLC. She also served, among others, on the board of directors of the American Cancer Society, the Prevent Cancer Foundation, and on numerous committees and advisory boards.

Bertagnolli holds a B.S.E. in biochemical engineering, an M.D. from the University of Utah College of Medicine and an M.A. in the science of medicine from Harvard University. 

Mr. Botha has served as a member of our board of directors since 2007. Mr. Botha has been with Sequoia Capital, a venture capital firm, since 2003, and has been a managing member of Sequoia Capital Operations, LLC since 2007. From 2000 to 2003, Mr. Botha served in a number of roles at PayPal, Inc., ultimately as the chief financial officer. Mr. Botha currently serves on the board of directors of Block, Inc. (formerly Square, Inc.), a provider of payments, financial and marketing services; MongoDB, Inc., a document-oriented database program developer; Unity, Inc., a 3D and VR content development platform; and a number of private companies. Mr. Botha has previously served on the board of directors of 23andme, a personal genetics company, from September 2017 through September 2024; Bird Global, a last-mile electric vehicle sharing company, from May 2018 through December 2022; and Eventbrite, Inc., an event management and ticketing platform, from October 2009 through June 2022. Mr. Botha holds a Bachelor of Science in Actuarial Science, Economics, and Statistics from the University of Cape Town and an M.B.A. from Stanford University. 

Dr. Chapman joined our board of directors in August 2019. Dr. Chapman is a co-founder of and advisor to Initiate Studios, a life sciences incubator, and BEVC, an early-stage investment fund, and is an adjunct lecturer in the department of bioengineering at Stanford University. She also served as chief business officer of Dynamics Special Purpose Corporation from March 2021 to June 2022. Prior to this, she served as head of Johnson & Johnson Innovation, Western North America, Australia and New Zealand from January 2017 to August 2019. Previously, Dr. Chapman held various roles with General Electric Company from 2012 to 2016, including as head of precision diagnostics at GE Healthcare Life Sciences, managing director of New Business Creation at GE Ventures, and head of healthcare investing at GE Ventures. Prior to that, she held operational roles in early and growth-stage startups and was a partner at Mohr Davidow Ventures for over 11 years, gaining extensive experience as a board member and board advisor for a wide variety of technology and data-enabled companies. Dr. Chapman currently serves as a member of the board of a venture capital fund as well as a number of private companies. Dr. Chapman is NACD (National Association of Corporate Directors) Directorship Certified®. Dr. Chapman holds a Bachelor of Arts degree in Biochemistry and a Doctor of Philosophy degree in Biochemistry and Molecular Biology from the University of Cambridge, United Kingdom. 

Steve Chapman is the chief executive officer of Natera and serves on the company’s board of directors.

Chapman is a leading authority on the commercialization of genetic testing. Under his leadership, Natera has launched 20 products that have transformed patient care, including two of the fastest growing genetic tests of all time. The company’s suite of products includes the Signatera™ oncology test for molecular residual disease, the Prospera™ transplant assessment test, the Renasight™ kidney gene panel which screens for genetic causes of chronic kidney disease, and the highly differentiated Panorama™ test serving patients in the non-invasive prenatal testing market. 

Before his appointment as CEO in 2019, Chapman held a number of other leadership positions at Natera including chief operating officer. Earlier in his career, he worked at Genzyme Genetics. He began his career as a researcher in the department of human genetics at the University of California Los Angeles (UCLA), where he designed arrays identifying SNPs associated with multiple sclerosis. 

Chapman serves on the board of directors for the American Clinical Laboratories Association (ACLA). In 2024, he was named one of the top healthcare technology CEOs by Healthcare Technology Report, as well as “BioTechnology Innovator of the Year” by BioTech Breakthrough. He has been a guest on CNBC and other shows and podcasts to share more about Natera’s impact on patient care in the field of personalized genetic testing and diagnostics. He has also authored multiple scientific papers. 

Chapman holds a bachelor’s degree in microbiology, immunology, and molecular genetics from UCLA, where he graduated with honors. 

Dr. Marcus has served as a member of our board of directors since March 2017. Dr. Marcus is currently an assistant professor of health professions at Hofstra University, and previously served as assistant professor and director of the Global Healthcare Management and Biomedical Informatics programs, and as department chair of the Pharmaceutical Business and Administrative Services program, at the Massachusetts College of Pharmacy and Health Sciences from April 2016 to July 2019. From 2015 to September 2017, Dr. Marcus served as a consultant and practice leader in the healthcare consulting practice of Exceptional Leaders International, a consulting company. From October 2012 to December 2015, Dr. Marcus served as chief executive officer and president of Calloway Laboratories, a provider of clinical toxicology laboratory services. Prior to that, Dr. Marcus held a variety of leadership roles with diagnostics, pharmacy benefit management and managed care companies. Dr. Marcus currently serves on the boards of directors of a number of private companies and non-profit organizations. She previously served on the board of directors of Triple S Management Corp., an insurance holding company, from 2017 to 2022, and served on the Centers for Medicare & Medicaid Services Advisory Panel on Clinical Diagnostic Laboratory Tests from 2015 to 2019. Dr. Marcus also serves on the board of directors of several private biotechnology companies. Dr. Marcus holds a CERT Certificate in Cybersecurity Oversight from the Software Engineering Institute at Carnegie Mellon University. Dr. Marcus holds a Bachelor of Arts in Spanish and Mathematics from Wesleyan University, an M.S.E. in Computer and Information Sciences from the University of Pennsylvania Moore School of Engineering, an M.B.A. from the Wharton School of the University of Pennsylvania, and a Doctorate of Health Administration from the Medical University of South Carolina.

Matthew Rabinowitz, Ph.D., is co-founder of Natera and currently serves as the executive chairman of its board of directors. From 2005-2019, he served as Natera’s chief executive officer.

Rabinowitz serves as a chairman, director and/or advisor to many companies and nonprofits involved in diagnostics, biotech, artificial intelligence (AI), health services, and nature conservation. Additionally, he manages an early stage technology venture fund focused on biotech, security, and AI. 

Companies Rabinowitz has founded have twice received the World Economic Forum Technology Pioneer award and thrice received Edison Awards in the United States. He has served as consulting professor in Aeronautics and Astronautics at Stanford, as visiting faculty in Genetics at Harvard, and has received the Scott Helt Award from the Institute of Electrical and Electronic Engineers. 

Rabinowitz has authored well over 100 patents and publications respectively, including papers in the top reproductive, transplant, and oncology journals. He led the development of the highest volume clinical genetic test in US history, which transformed pregnancy management, and oversaw the development of a technology that tracks tumor mutations in blood that has reshaped cancer management and received multiple FDA breakthrough designations. He also led the first whole genome polygenic modelling of embryos to prevent conferring disease risks to our children, as well as other breakthrough products. In 2024, Rabinowitz was named R&D Leader of the Year by R&D World. 

Rabinowitz studied electrical engineering and physics at Stanford University. He received the Levin and Terman awards, the top academic awards offered by each department, and a graduate fellowship to the school of engineering, where he completed his doctorate in electrical engineering.

Mr. Rosenman has served as a member of our board of directors since February 2017, and served as our Chief Financial Officer from February 2014 to January 2017. Prior to joining our company, he held the position of senior vice president — finance and chief financial officer at Gen-Probe Incorporated, a developer, manufacturer and marketer of diagnostic and screening products using nucleic acid probes, from June 2001 to August 2012, when Gen-Probe was acquired by Hologic, Inc., a developer, manufacturer and supplier of diagnostic products, medical imaging systems, and surgical products. From April 2012 to February 2014, Mr. Rosenman focused on his board memberships. Mr. Rosenman has served on the board of directors of DermTech, a molecular dermatology company, since 2017. Mr. Rosenman also previously served on the board of directors of Oxford Immunotec Global PLC, a commercial-stage diagnostics company, from 2017 to 2021, when the company was acquired by PerkinElmer; Vivus, Inc., a biopharmaceutical company, from 2013 to 2021; as well as Medistem, Inc., a stem cell therapy company, ARYx Therapeutics Inc., a private drug discovery and development company, Infinity Pharmaceuticals, Inc., a drug discovery and development company, and a number of privately held companies. Mr. Rosenman holds a B.B.A. in Accounting and Finance from Pace University and an M.B.A. in Finance from the Wharton School of the University of Pennsylvania.

Jonathan Sheena is a co-founder of our company. Mr. Sheena has served as a member of our board of directors since 2007, and served as our Chief Technology Officer from 2007 to December 2020. In 1999, Mr. Sheena co-founded PhoneSpots, Inc. (formerly PocketThis, Inc.), a mobile technology company serving mobile carriers worldwide. From June1999 to December 2007, Mr. Sheena held various roles at PhoneSpots, Inc. including vice president of product management and chief technology officer. Mr. Sheena holds a Bachelor of Science in Electrical Engineering and Computer Science, and a Master of Engineering in Electrical Engineering and Computer Science, from the Massachusetts Institute of Technology.

Ms. Williams-Brinkley joined our board of directors in March 2023. In January 2024, she formed RWB Advisory Services to focus on consulting and advisory services to healthcare organzations. Until January 2024, Ms. Williams-Brinkley served as president of Kaiser Foundation Health Plan of the Mid-Atlantic States, where she oversaw Kaiser Permanente’s care delivery and health plan operations in Washington, D.C., suburban Maryland, Baltimore, and Northern Virginia. Ms. Williams-Brinkley previously served as president of Kaiser Foundation Health Plan and Hospitals of the Northwest from November 2017 to June 2020. Prior to joining Kaiser Permanente, Ms. Williams-Brinkley served as president and chief executive officer of KentuckyOne Health, an affiliate of CommonSpirit Health and Kentucky’s largest integrated health system, from 2011 to 2017; as president and chief executive officer of Carondelet Health Network in Tucson, Arizona, an affiliate of Ascension Health, from 2008 to 2011; as president and chief executive officer of Memorial Health Care System in Chattanooga, Tennessee, an affiliate of CommonSpirit Health, from 2002 to 2008; and as corporate system vice president at CommonSpirit Health from 1998 to 2002. Ms. Williams-Brinkley has served on the board of directors of Travere Therapeutics, Inc., a biopharmaceutical company, since September 2021, and also currently serves on the board of directors of University of Phoenix and a number of not for profit organizations. Previously, she served as a member of the Board of Directors of Results Physiotherapy, a private care delivery company until it was acquired by Upstream Rehabilitation in 2021, and Chattem, Inc. until it was acquired by Sanofi in 2009. Earlier in her career, Ms. Williams-Brinkley held various nursing staff and management roles of increasing responsibility. Ms. Williams-Brinkley holds a Bachelor of Science and a Master of Science in nursing from De Paul University.